# IDeate-Lung01: HCP commentary report

> 248 verified statements (61 from speakers with a confirmed clinical role) from 54 commentary sources · 8 findings · updated Oct 20, 2026

## Report

- Trial: A Phase 2, Multicenter, Randomized, Open-label Study of Ifinatamab Deruxtecan (I-DXd), a B7-H3 Antibody Drug Conjugate (ADC), in Subjects With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) (IDeate-Lung01)
- NCT ID: NCT05280470
- Registry: https://clinicaltrials.gov/study/NCT05280470
- Sponsor: Daiichi Sankyo
- Phase: Phase 2
- Status: Active, not recruiting
- Version: v1.0.0, edition 1
- Accepted: 2026-10-20
- Last checked: 2026-10-20
- Release hash: bdc462dd7e41d9d9901cb2abfa66e086300797ba42d5e2ea31aa7c6d0a8ec517

## Counts

- HCP commentary sources screened: 80
- Sources cited by verified statements: 55
- Verified statements: 248
- From speakers with a confirmed clinical role: 61
- Findings: 8
- People found in screened sources: 40
- People identity-verified: 29
- Voices cited: 39

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

IDeate-Lung01 asks whether ifinatamab deruxtecan can shrink tumors in previously treated extensive-stage small-cell lung cancer. Clinicians in the sources reviewed for this edition question how response enthusiasm should shape treatment placement, which remains conditional. They welcome intracranial activity while raising concerns about response durability and chemotherapy-like toxicity. Their commentary leaves comparative benefit unresolved and does not establish the reasons for the filing withdrawal.

## Open Medical Affairs question

How should education distinguish risk-based redirection, closer observation, diagnostic uncertainty and trial-specific stopping rules?

Raised by the leading finding. The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. ILD raises patient-selection and stopping questions—not a blanket exclusion for poor pulmonary function
- F2. Response enthusiasm does not resolve durability, survival or the dose trade-off
- F3. The filing-withdrawal discussion sharpens the need for comparative evidence, but does not establish the FDA's reasoning
- F4. CNS activity is clinically compelling to speakers, but protection and treatment substitution remain unproven
- F5. Placement depends on prior tarlatamab, access, performance status and feasible alternatives
- F6. Chemotherapy-like familiarity supports adoption, but does not mean low toxicity
- F7. A credible target does not yet identify the preferred ADC or a selection biomarker
- F8. Combination optimism is a research rationale, not evidence for adding treatment

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding.

| Finding | Statements | Passages | Sources | Named voices | Counterview | Limitations |
| --- | ---: | ---: | ---: | ---: | --- | ---: |
| F1 | 17 | 18 | 3 | 5 | recorded | 3 |
| F2 | 32 | 29 | 21 | 18 | recorded | 3 |
| F3 | 22 | 16 | 9 | 13 | recorded | 3 |
| F4 | 25 | 18 | 6 | 6 | recorded | 4 |
| F5 | 36 | 31 | 8 | 12 | recorded | 5 |
| F6 | 22 | 25 | 6 | 7 | recorded | 3 |
| F7 | 33 | 33 | 11 | 12 | recorded | 4 |
| F8 | 8 | 9 | 4 | 5 | none recorded | 2 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Passages supporting | Passages giving context | Sources by kind | Feeds the Medical Affairs question |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- | --- |
| F1 | 7 | 5 | 3 | 0 | 2 | 18 | 8 | 3 podcasts and video | yes |
| F2 | 10 | 1 | 2 | 6 | 13 | 42 | 6 | 16 posts and articles, 5 podcasts and video | yes |
| F3 | 7 | 4 | 1 | 1 | 9 | 29 | 4 | 6 posts and articles, 3 podcasts and video | yes |
| F4 | 6 | 1 | 0 | 4 | 14 | 29 | 16 | 2 posts and articles, 4 podcasts and video | yes |
| F5 | 16 | 12 | 4 | 1 | 3 | 42 | 16 | 5 posts and articles, 3 podcasts and video | yes |
| F6 | 4 | 6 | 1 | 4 | 7 | 25 | 10 | 1 post or article, 5 podcasts and video | yes |
| F7 | 10 | 5 | 0 | 8 | 10 | 39 | 17 | 7 posts and articles, 4 podcasts and video | yes |
| F8 | 4 | 3 | 0 | 1 | 0 | 8 | 2 | 1 post or article, 3 podcasts and video | yes |

### Trial dimensions

- Primary endpoint: Percentage of Participants With Objective Response Rate (ORR) Based on Blinded Independent Central Review (BICR) Following Treatment With I-DXd in Participants With Pretreated ES-SCLC: F2 (13 shared claims), F3 (1 shared claims)
- Secondary endpoints: F2 (10 shared claims), F6 (2 shared claims)
- Population and setting: F1 (1 shared claims), F2 (4 shared claims), F4 (1 shared claims), F5 (8 shared claims), F6 (1 shared claims)
- The comparison: F2 (6 shared claims)
- Safety and tolerability: F1 (13 shared claims), F2 (2 shared claims), F5 (1 shared claims), F6 (11 shared claims)
- Design and conduct: F2 (4 shared claims), F3 (1 shared claims), F4 (2 shared claims), F5 (1 shared claims)

## Sample findings

Paraphrased; the full report links each statement to its source.

### F4. CNS activity is clinically compelling to speakers, but protection and treatment substitution remain unproven

In a YouTube discussion, a speaker asked whether I-DXd or other B7-H3 antibody-drug conjugates had been studied for activity in brain metastases.

Source: YouTube video, 2026-09-10.

### F3. The filing-withdrawal discussion sharpens the need for comparative evidence, but does not establish the FDA's reasoning

An X-thread contributor asked whether interstitial lung disease was a factor in withdrawal of the I-DXd application.

Source: X thread, 2026-09-25.

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 8 | Titles free |
| Detailed analysis | 9 sections | Paid |
| Verified statements with short source quotes and links | 248 | Paid |
| Trial aspects mapped | 12 | Free |
| Sources with links | 55 | Counts free |
| Speaker attribution for cited voices | 39 | Paid |

## Trial aspects

12 discussed · 0 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Percentage of Participants With Objective Response Rate (ORR) Based on Blinded Independent Central Review (BICR) Following Treatment With I-DXd in Participants With Pretreated ES-SCLC | discussed | 13 | 13 |
| Secondary endpoints | discussed | 11 | 12 |
| Population and setting | discussed | 12 | 8 |
| The comparison | discussed | 6 | 4 |
| Safety and tolerability | discussed | 24 | 4 |
| Design and conduct | discussed | 7 | 2 |
| CNS activity, subgroup interpretation and local-treatment implications | discussed | 23 | 6 |
| Pulmonary work-up, monitoring and treatment redirection | discussed | 16 | 3 |
| Comparative confirmation and interpretation of regulatory events | discussed | 20 | 8 |
| Sequencing, access, patient fitness and trial discussions | discussed | 35 | 7 |
| Target rationale, biomarkers and differentiation among ADCs | discussed | 33 | 11 |
| Combination rationale and unresolved resistance | discussed | 8 | 4 |

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

## Sources

| Channel | Screened | Cited |
| --- | ---: | ---: |
| X threads | 58 | 43 |
| Bluesky threads | 13 | 5 |
| YouTube | 5 | 4 |
| Podcasts | 4 | 2 |
| Publications (primary source, cited for context) | not screened | 1 |

- Screened window: 2023-04-01 to 2026-10-16
- Cited window: 2023-04-27 to 2026-10-08
- Retrieved: 2026-10-19

Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: A Phase 2, Multicenter, Randomized, Open-label Study of Ifinatamab Deruxtecan (I-DXd), a B7-H3 Antibody Drug Conjugate (ADC), in Subjects With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) (IDeate-Lung01)
- Registry: NCT05280470 (https://clinicaltrials.gov/study/NCT05280470)
- Study IDs: DS7300-127 · 2022-000503-13 · 2041220019 (jRCT)
- Sponsor: Daiichi Sankyo
- Collaborators: Merck Sharp & Dohme LLC
- Design: Phase 2 · interventional, randomized, parallel, phase2
- Status: Active, not recruiting
- Enrollment: 187 (actual)
- Start: 2022-03-09 (actual)
- Primary completion: 2025-03-03 (actual)
- Primary endpoint: Percentage of Participants With Objective Response Rate (ORR) Based on Blinded Independent Central Review (BICR) Following Treatment With I-DXd in Participants With Pretreated ES-SCLC (Up to approximately 36 months)
- Intervention: Ifinatamab Deruxtecan (I-DXd) (drug)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- For 1 recording, a transcript separated by speaker was not available, so quotes come from the original automatic transcript and may lack speaker labels.
- Some clinician views in the sources used in this report are not yet captured as evidence in this edition; the next refresh takes them up.
- Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
- Out of scope: 3 passages in the reviewed sources discuss other trials or topics outside this report's scope; they are not part of this edition.
- 212 statements in the sources reviewed for this edition discuss other treatment settings or topics unrelated to this trial's question and are not included.
- Further source limits apply, so some matching discussion may be missing.
- The sources reviewed for this edition do not represent all HCP discussion, and repeated posts or shared presentations cannot be counted as independent clinician agreement.
- Searches emphasized trial identifiers, drug names and selected relapsed-disease terms. Unnamed references and transcription variants may be absent; eight additional sources were not read, and several passages in included discussions were not fully evaluated.
- Some participants could not be identified reliably, and one recording relied on its available transcript. Anonymous views have not been assigned to faculty from a program listing, a host's address or an account identifier.
- The unidentified long-form X author's clinical role is unknown. The author's regulatory and comparative arguments should not be treated as physician consensus or an FDA explanation.
- The discussion spans different studies, analyses and dates. Earlier Phase I/II findings, IDeate-Lung01 interim and later reports, and IDeate-Lung02 plans cannot be combined as one dataset or used to infer a change of mind.
- Reported efficacy and safety values differ across sources. These differences were preserved rather than reconciled, pooled or converted into treatment comparisons; Ergün's post does not specify an OS unit.
- The complete protocol and an exact approved I-DXd label were not available. Source reports of regulatory developments, trial management and anticipated access do not establish current prescribing instructions or availability.
- The eligibility described by Hann included ECOG 0–1 and treated or untreated asymptomatic brain metastases. The discussion does not establish applicability to poorer performance status or symptomatic CNS disease.
- A case-discussion turn used 1 mg/kg for tarlatamab and a later turn used 1 mg. These were tentative, patient-specific statements, not reconciled dosing guidance.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, accepted 2026-10-20: current edition

Last checked for new commentary 2026-10-20. No corrections. Versions follow semver: a new or changed finding is a minor version, more evidence without a material change is a patch.

## Offer

- Size: Standard (248 verified statements)
- Current edition: $1,250. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of weekly updates: $2,200
- 6 months of weekly updates: $3,100
- 12 months of weekly updates: $4,400
- Optional identity linkages (12-month updates only, product updates-12-identities; speakers are named and described in every report): NPI and other verified IDs at $15 per identity-verified person in the edition at purchase (29 now), at most $1,250; people verified later in the term at no charge
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/ideate-lung01-nct05280470
- Agents: POST https://www.erudio.com/api/orders with {"report": "ideate-lung01-nct05280470", "product": "edition" | "updates-3" | "updates-6" | "updates-12" | "updates-12-identities", "buyer_email": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user (and a pay_url your own MPP or x402 payment client can pay over HTTP 402, when offered), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=ideate-lung01-05280470

## Cite

Erudio Health. IDeate-Lung01 (NCT05280470): HCP commentary report. Edition 1, v1.0.0. Accepted Oct 20, 2026. https://www.erudio.com/reports/ideate-lung01-nct05280470

## Machine access

- JSON: https://www.erudio.com/reports/ideate-lung01-nct05280470.json
- Markdown: https://www.erudio.com/reports/ideate-lung01-nct05280470.md
- MCP: https://mcp.erudio.com/mcp, tool `get_report_card` with `{"slug": "ideate-lung01-05280470"}`